Toggle Main Menu Toggle Search

Open Access padlockePrints

Lp(A): When and how to measure it

Lookup NU author(s): Dr R Neely



This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


© The Author(s) 2020. Lipoprotein(a) has long been regarded as a risk factor for cardiovascular disease; however, its routine use in clinical practice has been hampered by difficulties inherent in the measurement of this complex lipoprotein. The major challenges relate to its size heterogeneity and related issues including (1) use of appropriate calibrators (2) standardization of calibration protocols (3) traceability and (4) reporting units. In the UK, results from the current EQA schemes for lipoprotein(a) suggest that there is considerable work required to standardize lipoprotein(a) measurement. This is becoming increasingly pertinent with the increasing recognition of lipoprotein(a) as an independent risk factor for cardiovascular disease in international guidelines and the emergence of novel antisense therapies to effectively reduce lipoprotein(a). This article raises awareness of the importance of measurement of lipoprotein(a) for the assessment of cardiovascular disease risk and gives guidance to clinical laboratories regarding choice of appropriate assays.

Publication metadata

Author(s): Cegla J, France M, Marcovina SM, Neely RDG

Publication type: Review

Publication status: Published

Journal: Annals of Clinical Biochemistry

Year: 2021

Volume: 58

Issue: 1

Pages: 16-21

Print publication date: 01/01/2021

Online publication date: 28/10/2020

Acceptance date: 01/10/2020

ISSN (print): 0004-5632

ISSN (electronic): 1758-1001

Publisher: SAGE Publications Ltd


DOI: 10.1177/0004563220968473

PubMed id: 33040574